Base Editors Flex Sights on Sickle-Cell Disease

Frangoul H , Altshuler D , Cappellini D , et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021; 384:252–260. DOI: 10.1056/NEJMoa2031054.

Urnov FD . The Cas9 hammer—and sickle: A challenge for genome editors. CRISPR J. 2021; 4:6–13. DOI: 10.1089/crispr.2021.29120.fur.

Chu SH , Packer M , Rees H , et al. Rationally designed base editors for precise editing of the sickle-cell disease mutation. CRISPR J. 2021; 4:169–177.

Davies K , Komor AC , Gaudelli NM . The beginning of base editing: An interview with Alexis C. Komor and Nicole M. Gaudelli. CRISPR J. 2019; 2:81–90. DOI: 10.1089/crispr.2019.29050.kda.

Davies K . Precision chemistry on the genome: An interview with David R. Liu. Human Gene Therapy., 2021; 32:237–242. DOI:10.1089/hum.2021.29151.int.

Anzalone AV , Randolph PB , Davis JR , et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019; 576:149–157. DOI: 10.1038/s41586-019-1711-4.

Koblan LW , Erdos MR , Wilson C , et al. In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice. Nature. 2021; 589:608–614. DOI: 10.1038/s41586-020-03086-7.

Suh S , Choi EH , Leinonen H , et al. Restoration of visual function in adult mice with an inherited retinal disease via adenine base editing. Nat Biomed Eng. 2021; 5:169–178. DOI: 10.1038/s41551-020-00652-2.

Gaudelli NM , Lam DK , Rees HA , et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat Biotech. 2020; 38:892–900. DOI: 10.1038/s41587-020-0491-6.

Yu Y , Leete TC , Born DA , et al. Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity. Nat Comm. 2020; 11:2052. DOI: 10.1038/s41467-020-15887-5.

Anzalone AV , Koblan LW , Liu DR . Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nat Biotech. 2020; 38:824–844. DOI: 10.1038/s41587-020-0561-9.

Blackwell RQ , Oemijati S , Pribadi W , et al. Hemoglobin G Makassar: β6 Glu->Ala. BBA—Protein Struct. 1970; 214:396–401. DOI: 10.1016/0005–2795(70)90297-7.

Cradick TJ , Fine EJ , Antico CJ , Bao G . CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucl Acids Res. 2013; 42:9584–9592. DOI:10.1093/nar/gkt714.

Walton RT , Christie KA , Whittaker MN , Kleinstiver BP . Unconstrainted genome targeting with near PAMless engineered CRISPR-Cas9 variants. Science. 2020; 368:290–296. DOI: 10.1126/science.aba8853.

Chatterjee P , Jakimo N , Lee J , et al. An engineered ScCas9 with broad PAM range and high specificity and activity. Nat Biotech. 2020; 38:1154–1158. DOI: 10.1038/s41587-020-0517-0.

Dever DP , Bak RO , Reinisch A , et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016; 539:384–389. DOI: 10.1038/nature20134.